Lixoft

Pharmacometrics Softwarelixoft.com

Lixoft develops MonolixSuite, an interoperable pharmacometrics software suite for population PK/PD modeling, NCA/bioequivalence analysis, and clinical trial simulation, serving pharmaceutical and biotechnology companies, CROs, and academic institutions worldwide.

Company typePublic
Founded2011
HeadquartersAntony, France
Headcount11–50
GTM typeB2B
OfferingSoftware

What Lixoft does

Lixoft, founded in 2011 and based in Antony, France, develops modeling and simulation software for advanced model-based drug development, with a core focus on pharmacometrics. Its flagship product, MonolixSuite, is a set of three fully interoperable applications: Monolix for parameter estimation in non-linear mixed effect models and model diagnosis, PKanalix for compartmental and non-compartmental analysis and bioequivalence studies, and Simulx for clinical trial simulations. The suite enables a seamless workflow from data visualization through population PK/PD modeling to clinical trial simulation, with compatibility for SAS and Excel datasets and features such as integrated bootstrap, sparse data NCA, and customizable plotting.

Lixoft serves pharmaceutical and biotechnology companies as its primary segment, with contract research organizations (CROs) and academic/research institutions as secondary segments. The company operates a quote-based annual licensing model for commercial customers, supplemented by discounted or free academic licensing to build a pipeline of trained users. Distribution relies on direct enterprise sales, inside sales via evaluation and demo request forms, and event-driven demand generation through scientific conferences (ACoP, ACCP, ISSX, DPHARM) and on-demand workshops. Lixoft has been integrated into Simulations Plus, Inc. (NASDAQ: SLP), which itself has entered an agreement to be acquired by Altaris, LLC with plans to combine with Chemical Computing Group (CCG), pending regulatory and shareholder approvals.

Lixoft firmographics

Firmographics

Name: Lixoft
Legal name: Simulations Plus, Inc.
Website: https://lixoft.com
Company type: Public
Founded year: 2011
Operating status: Operating
Headcount range: 11–50 employees
Short description: Lixoft develops MonolixSuite, an interoperable pharmacometrics software suite for population PK/PD modeling, NCA/bioequivalence analysis, and clinical trial simulation, serving pharmaceutical and biotechnology companies, CROs, and academic institutions worldwide.
Ownership category
akta.pro rank

Lixoft industry classification

Industry

Product category: Pharmacometrics Software
NAICS: Software Publishers (5132), Computer Systems Design Services (541512)
SIC: Services-Commercial Physical & Biological Research (8731), Services-Computer Integrated Systems Design (7373)
akta.pro industry: PRIMARYHLAIALAG
Clinical Pharmacology & Pharmacometrics (Modeling & Simulation)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAFAM
In Silico / Computational Toxicology & PK/PD Modeling
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)

Keywords

Pharmacometrics software
Population PK modeling
Clinical trial simulation
Non-linear mixed effects
Drug development modeling

Where Lixoft is headquartered

Location

Headquarters

HQ city: Antony
HQ country: France
HQ region: Europe

Markets served

Lixoft business model

Business model

GTM type: B2B
Offering type: Software
Cost components: Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

Software Licenses and Subscriptions: MonolixSuite is offered as a software suite with licensing to pharmaceutical, biotech companies, and academic institutions. The software supports evaluation downloads, academic licenses, and commercial licenses, suggesting a subscription or perpetual license model.

Pricing tiers

Model	Billing	Price
Subscription	Annual	Commercial License
Subscription	Annual	Academic License

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Lixoft product offering

Product offering

Core offering

Lixoft develops the MonolixSuite, an integrated suite of pharmacometrics modeling and simulation software applications. The suite includes Monolix for non-linear mixed effect (NLME) model parameter estimation and model diagnosis, PKanalix for compartmental analysis, non-compartmental analysis and bioequivalence studies, and Simulx for clinical trial simulations. These fully interoperable applications support model-informed drug development (MIDD) workflows for pharmaceutical, biotech, contract research and academic researchers.

Product overview

MonolixSuite™ is a unified platform-plus-modules software suite for pharmacometrics analysis. The core suite comprises three integrated applications: Monolix® for non-linear mixed effect model parameter estimation and model diagnosis, PKanalix® for compartmental and non-compartmental analysis and bioequivalence studies, and Simulx® for clinical trial simulations. These fully interoperable applications provide a complete modeling and simulation workflow from data visualization and non-compartmental analysis to population modeling and simulations, enabling seamless transfer of code and profiles between modules.

Differentiator

Problem solved

Functional benefit

Products and services

MonolixSuite 2024
Monolix
PKanalix
Simulx

Quantifiable outcome

Over 7,000 downloads in 2023
+3 more outcomes

Companies that use Lixoft

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Lixoft technology and API

Technology

Technology focussed Yes

API detail

Has API: No
API docs
API detail

Core technology

AI maturity

App detail

Feature9 records

Lixoft partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves5 records

Expansion highlights4 records

Lixoft competitors and assessment

Company assessment

Emerging players

nlmixr: nlmixr is an open-source R- and Python-based nonlinear mixed-effects modeling ecosystem and direct functional substitute for MonolixSuite's NLME capabilities, often adopted in academic pharmacometrics groups and increasingly in industry.
Pumas: Pumas is a Julia-based open-core platform for population PK/PD and clinical trial simulation developed from academic roots; it targets the same pharmacometrician user base as MonolixSuite and represents an emerging, lower-cost alternative for sponsors building modern scientific computing stacks.
Chemical Computing Group (CCG): CCG provides molecular design software (MOE) and is announced to combine with Simulations Plus under Altaris; once combined, it will sit within the same platform portfolio as MonolixSuite, representing a tightly related but distinct chemistry/computational drug discovery peer.
InSilicoTrials: InSilicoTrials provides a cloud marketplace of in silico trial and PBPK/PK simulation tools, sharing the pharma model-informed drug development buyer with MonolixSuite while distributing competing modeling capabilities through a different (cloud marketplace) commercial model.

Broad incumbents

Simulations Plus: Simulations Plus is Lixoft's parent (NASDAQ: SLP) and the broader commercial owner of MonolixSuite, while also offering adjacent modeling and simulation platforms (GastroPlus, ADMET Predictor, DILIsym) that overlap with similar pharma R&D customers.
Schrödinger: Schrödinger is a large computational chemistry and molecular simulation platform serving pharma R&D; while focused on physics-based modeling rather than population PK/PD, its platform ambitions overlap with MonolixSuite at the customer (large pharma modeling and simulation group) and broader MIDD discussion level.
Dassault Systèmes (BIOVIA): Dassault Systèmes BIOVIA provides scientific informatics and molecular modeling software to life sciences R&D; it serves overlapping pharma modeling and simulation buyer groups with broader discovery and development suites that can substitute for or integrate with MonolixSuite.
ICON (LAP&P / NONMEM): ICON acquired Linear Approach to Pharmacokinetic Analysis (LAP&P) and the commercial rights to NONMEM, the historical gold-standard NLME platform, making it a broad incumbent competing directly with MonolixSuite for population PK/PD seats in large pharma.

Direct peers

Certara: Certara is the dominant commercial pharmacometrics software provider (Phoenix WinNonlin, Phoenix NLME) and the primary direct competitor to MonolixSuite for population PK/PD modeling, NCA, and regulatory-grade clinical pharmacology workflows in pharmaceutical companies.
Metrum Research Group: Metrum Research Group is a pharmacometrics-focused CRO and software-adjacent consultancy that serves the same pharma/biotech sponsors with population PK/PD modeling and MIDD services, often interfacing with the same Monolix/NONMEM ecosystem.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Lixoft financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Lixoft leadership team

Management profile

Number of profiles

Profiles1 record

Lixoft funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Lixoft M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lixoft

What does Lixoft do?

Is Lixoft a public or private company?

Lixoft is a public company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Lixoft founded?

Lixoft was founded in 2011. It employs 11 to 50 people.

Where is Lixoft based?

Lixoft is headquartered in Antony, France, in the Europe region.

How does Lixoft make money?

One revenue line is on record: software Licenses and Subscriptions.

Who are Lixoft's main competitors?

Emerging players on record are nlmixr, Pumas, Chemical Computing Group (CCG) and InSilicoTrials. Broad incumbents are Simulations Plus, Schrödinger, Dassault Systèmes (BIOVIA) and ICON (LAP&P / NONMEM). Direct peers are Certara and Metrum Research Group.

Does Lixoft have an API?

No public API is recorded for Lixoft.

What industry is Lixoft in?

Lixoft's product category is Pharmacometrics Software. Its primary akta.pro industry code is HLAIALAG, Clinical Pharmacology & Pharmacometrics (Modeling & Simulation), with a secondary code of HLAGAFAM, In Silico / Computational Toxicology & PK/PD Modeling. Its NAICS code is 5132 and its SIC code is 8731.